Skip to main content
. 2015 Sep 3;10(9):e0137285. doi: 10.1371/journal.pone.0137285

Table 1. Acquisition parameters for the applied MR-sequences (A-F).

A) T1w VIBE Dixon cor. B) T1w FLASH ax. pre contrast C) T2w HASTE ax. D) EPI DWI ax. (b-values: 0, 500, 1000) E) T2w TSE ax. F) T1w dyn. VIBE ax. G) T1w FLASH fs ax. post contrast
Echo time / Repetition time (ms) 1.23 + 2.46 (1st + 2ndecho) / 3.6 2.15 / 1510 117 / 1500 86 / 11900 97 / 2840 1.51 / 3.75 3.3 / 1700
Inversion time(ms) n/a 1200 n/a n/a n/a n/a 1200
Flip angle (°) 10 20 160 90 120 9 20
Field of view (mm) 500 450 450 380 400 400 450
Phase FOV (%) 65.6 81.3 81.3 75.0 75.0 75.0 81.3
Parallel imaging acceleration factor n/a 2 2 2 2 2 2
Slice thickness (mm) 3.1 5.0 5.0 5.0 7.0 3.5 7.5
Fat saturation (yes/no) no no no yes yes yes Yes
i.v. contrast (yes /no) no no no no no yes yes

A) A coronal T1w in and opposed phase Volumetric Interpolated Breath-hold Examination (VIBE) for calculation of the Dixon-based fat-/water-images as well as the μ-map.

B) An axial, pre-contrast T1w Fast Low Angle Shot (FLASH).

C) An axial T2w 2D half Fourier acquisition single shot turbo spin echo (HASTE).

D) An axial diffusion weighted echo planar sequence (EPI DWI) with B values of 0, 500 and 1000 s/mm2.

E) An axial T2w fat saturated turbo spin echo (TSE) sequence in breath-hold.

F) A dynamic axial T1w VIBE. Four repetitive scans were performed (pre-contrast, arterial phase [20s delay], portal venous phase [60 sec delay], venous phase [100 sec delay]) after i.v.-injection of 0.1 ml/kg body weight Gadobutrol (Gadovist®, Bayer Healthcare, Berlin, Germany).

G) An axial post-contrast T1w FLASH.